| All CMR | Sustained CMR | PMD | P value |
---|---|---|---|---|
Median Age (years) | 60 (35–80) | 62 (35–74) | 59 (41–80) | 0.408 |
Sex (Male:Female) | 24:16 | 5:9 | 19:7 | 0.021 |
ECOG status | Â | Â | Â | Â |
• 0 | 3 | 3 | 0 |  |
• 1 | 35 | 11 | 24 | 0.013 |
• 2 | 2 | 0 | 2 |  |
Primary site | Â | Â | Â | Â |
• Right colon | 9 | 5 | 4 | 0.149 |
• Left colon | 31 | 9 | 22 |  |
T staging | Â | Â | Â | Â |
• T3 | 16 | 7 | 9 | 0.266 |
• T4 | 18 | 6 | 12 |  |
• Tx | 6 | 1 | 5 |  |
N staging | Â | Â | Â | Â |
• N0 | 2 | 1 | 1 |  |
• N1 | 15 | 6 | 9 | 0.432 |
• N2 | 18 | 6 | 12 |  |
• Nx | 5 | 1 | 4 |  |
KRAS status | Â | Â | Â | Â |
• Wild type | 29 | 11 | 18 | 0.355 |
• Mutation | 8 | 1 | 7 |  |
• Unknown | 3 | 2 | 1 |  |
Metastatic Site | Â | Â | Â | Â |
• Liver | 17 | 3 | 14 | 0.049 |
• Lung | 7 | 3 | 4 | 0.416 |
• Lymph node | 20 | 8 | 12 | 0.520 |
• Peritoneal | 11 | 4 | 7 | 0.914 |
• Others | 4 | 2 | 2 | 0.520 |
Chemotherapy regime | Â | Â | Â | Â |
• XELOX | 29 | 9 | 20 |  |
• FOLFOX | 5 | 3 | 2 |  |
• XELIRI | 2 | 1 | 1 | 0.989 |
• FOLFIRI | 2 | 1 | 1 |  |
• XELODA | 2 | 0 | 2 |  |
Biological agent | Â | Â | Â | Â |
• None | 16 | 9 | 7 |  |
• Bevacizumab | 8 | 1 | 7 | 0.021 |
• Cetuximab | 16 | 4 | 12 |  |
• Median number of chemotherapy cycle to achieve complete metabolic response (CMR) | 4 (3–12) | 5 (4–12) | 4 (3–10) | 0.234 |
• Median number of chemotherapy cycles received after CMR was achieved | 3 (0–8) | 3 (0–8) | 3 (0–8) | 0.980 |